The event brought together staff, researchers and clinicians to reflect on four decades of achievement and hear from leading figures in toxicology, psychiatry and clinical research, including Professor Ian Whyte, Professor Gregory Carter, Professor Geoff Isbister and Professor Andrew Dawson.

The global legacy of the hospital’s research was fundamentally shaped by the foundational work of Professors Ian Whyte, Andrew Dawson, and Greg Carter. In 1987, Professor Whyte co-founded HATS and established a comprehensive patient case register that became the foundation for decades of rigorous clinical trial data.

Working alongside Professor Whyte, Professor Dawson expanded the department's public health footprint, utilising HATS data to pioneer global models of care, trace early drug-toxicity signals, and influence international chemical safety regulations.

Recognising the critical intersection between acute self-poisoning and mental health, Professor Carter integrated a specialised consultation-liaison psychiatry service into HATS in 1995. Together, the trio collaborated on revolutionary psychiatric-toxicological interventions, most notably the internationally acclaimed "Postcards from the EDge" project - a landmark randomised controlled trial that demonstrated how a simple, non-obligatory postcard intervention drastically reduced repetitions of deliberate self-poisoning.

This strong foundation paved the way for the Mater's dedicated Clinical Toxicology Research Group, working in partnership with the University of Newcastle, to consistently deliver high-impact studies that redefine global medical guidelines.

Today, under the leadership of Professor Geoff Isbister, the department hosts critical multicentre initiatives like the Australian Snakebite Project (ASP) and the Australian Toxicology Monitoring (ATM) study. Notably, it features one of the few specialised laboratories globally capable of measuring precise venom and antivenom concentrations.

Through four decades of continuous investigation into paracetamol poisoning, drug-induced cardiotoxicity, behaviourally disturbed adult care, and envenomation treatments, the Mater has seamlessly unified pharmacology and mental health to drastically optimise patient outcomes worldwide.

Congratulations to HATS on this remarkable milestone.